Nephro Care India Limited Stock Price Today (NSE: NEPHROCARE)

Nephro Care India Limited

NEPHROCAREHospital
68.85+0.00 (+0.00%)
Market Closed

Fundamental Score

...

Nephro Care India Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Nephro Care India Limited share price today is 68.85, up +0.00% on NSE/BSE as of 2 June 2026. Nephro Care India Limited (NEPHROCARE) is a Small-cap company in the Hospital sector with a market capitalisation of 220.67 (Cr). The 52-week high for NEPHROCARE share price is 183.00 and the 52-week low is 51.65. At a P/E ratio of 65.09x, NEPHROCARE is currently trading above its industry average P/E of 52.84x. The company has a Return on Equity (ROE) of 8.38% and a debt-to-equity ratio of 0.00.

Nephro Care India Limited Share Price Chart — NSE/BSE Historical Performance

No data
High
88.90
Low
68.85
Volume
15.3K
Change
-7.06%

Nephro Care India Limited share price chart: -7.06% return over the past month. 52-week high ₹183.00, 52-week low ₹51.65.

Nephro Care India Limited — Last 10 Trading Days

DateOpenHighLowCloseVolume
80.0083.1079.0080.2516.00K (Cr)
80.0083.8078.0078.4030.00K (Cr)
85.0085.0078.3579.5522.00K (Cr)
88.0088.0085.3587.008.80K (Cr)
80.8083.4080.5582.8513.20K (Cr)
80.5081.9580.0080.553.20K (Cr)
87.5088.9086.1588.6021.60K (Cr)
86.3588.9086.0086.357.20K (Cr)
55.9058.5053.0058.2515.60K (Cr)
59.0059.0051.6552.301.11L (Cr)

Nephro Care India Limited — Last 12 Months Price History

MonthOpenHighLowCloseChange
80.5088.0078.0080.25-0.31%
55.9088.9053.0088.60+58.50%
63.5063.5051.6552.30-17.64%
101.20116.0570.0082.45-18.53%
112.25123.0095.00100.20-10.73%
131.20131.40107.50110.50-15.78%
131.95156.35131.95148.00+12.16%
140.10145.00131.35139.00-0.79%
154.00173.95133.55142.85-7.24%
146.90183.00133.05155.05+5.55%
117.20150.0099.95145.35+24.02%
136.95141.00115.50116.90-14.64%

AI Research Briefing

Powered by Gemini · 2026-04-13

Expensive micro-cap dialysis play with GST risk; avoid until valuation becomes rational.

Research Confidence
6.0/10Moderate
MICRO-CAP DARK HORSEBreakdown - 1M: -1.8%, 3M: -19.27% [cite: brief]Expensive - P/E of 65.09x vs industry P/E of 52.84x [cite: brief]

WHAT'S HAPPENING NOW (last 2-4 weeks)

Nephro Care is fighting a Cr GST bill in High Court after an appeal was blocked. A significant price movement was observed on April 9, 2026.

CORE STORY (THE REAL GAME)

Why Now
  • Sales CAGR 5Y of 143.29%
  • InCred Securities initiated coverage with an 'ADD' rating and a target price of ₹613
  • Asset-light model with 52% of clinics operating within partner hospitals and PPP clinics
Potential Catalysts
  • Significant order wins
  • Successful resolution of GST issue
  • Faster-than-expected expansion of dialysis centers
Key Risks
  • Micro/SME cap - liquidity risk
  • High P/E of 65.09x vs industry P/E of 52.84x [cite: brief]
  • GST bill of ₹2.51 Cr
Institutional Activity

FII decreased holdings by 0.03%, DII decreased holdings by 1.2% [cite: brief].

Macro Context

Growing demand for healthcare services in India provides a tailwind.

Cash Flow Quality

No - Free Cash Flow 5Y: ₹-22.86 Cr [cite: brief]

3–6 Month Outlook

3-6 month thesis: Expect a correction as valuation normalizes. Monitor for successful resolution of GST issue and execution of expansion plans.

Primary Thesis Risk

Overvaluation and reliance on government contracts create significant downside risk.

For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.

Returns & Performance

Poor

Return on Equity (ROE)

8.38%

Profit generated per ₹1 of shareholder equity

Poor

Return on Capital (ROCE)

11.27%

Returns generated on total capital deployed

Excellent

Oper. Profit Margin (5Y Avg)

16.80%

Average operating profit margin over 5 years

Dividend Yield

0.00%

Annual dividend as % of current share price

Nephro Care India Limited Valuation Check

Poor

Price to Earnings (P/E)

65.09x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

52.84x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

61.47%

% shares held by company founders/management

Poor

FII Holding

3.47%

% shares held by foreign institutional investors

Poor

DII Holding

1.04%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Poor

Profit Growth (Quarterly YoY)

-11.42%

Net profit growth vs same quarter last year

Excellent

Revenue Growth (Quarterly YoY)

122.33%

Revenue growth vs same quarter last year

Excellent

Revenue Growth (5-Year CAGR)

143.29%

Compounded annual revenue growth over 5 years

Excellent

EPS Growth (5-Year CAGR)

16.80%

Earnings per share growth over 5 years

Excellent

Net Profit Growth (5-Year CAGR)

210.58%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Excellent

Debt to Equity Ratio

0.00x

Total debt ÷ equity. Below 0.5 = financially healthy

Excellent

Interest Coverage Ratio

26.61x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

-22.86 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Nephro Care India Limited Fundamental Analysis & Valuation Benchmarking

Educational evaluation of NEPHROCARE across key market metrics for learning purposes.

Positive Indicators

9 factors identified

Strong Operating Margins (16.80%)

Observation: Healthy 5-year operating margins indicate pricing power and cost control.

Analysis: OPM >15% suggests operational efficiency and competitive advantages.

Strong Revenue Growth (122.33%)

Observation: Healthy sales growth indicates market demand and execution capability.

Analysis: Revenue growth >15% suggests strong market position and growth potential.

Consistent Growth Track Record (143.29% CAGR)

Observation: Strong 5-year sales compound annual growth rate.

Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.

Excellent EPS Growth (16.80% CAGR)

Observation: Outstanding 5-year earnings per share compound growth.

Analysis: EPS CAGR >15% indicates strong wealth creation potential.

Strong Profit Growth Track Record (210.58% CAGR)

Observation: Consistent 5-year profit compound annual growth rate.

Analysis: Profit CAGR >15% demonstrates scalable business model.

Debt-Free Balance Sheet (D/E: 0.00)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns.

Strong Interest Coverage (26.61x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk.

Balanced Promoter Holding (61.47%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

6 factors identified

Below-Average Return on Equity (8.38%)

Observation: Returns on equity are below industry benchmarks.

Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.

Premium Valuation Risk (P/E: 65.09x)

Observation: High valuation multiples may limit upside potential.

Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.

Profit Decline Concern (-11.42%)

Observation: Significant year-over-year profit contraction observed.

Analysis: Declining profitability requires investigation into underlying causes.

Negative Free Cash Flow (₹-22.86 Cr over 5Y)

Observation: Cash outflows exceed inflows.

Analysis: Negative FCF requires analysis of capital expenditure cycle.

Limited Institutional Interest (FII+DII: 4.51%)

Observation: Low institutional participation may affect liquidity.

Analysis: Limited institutional interest may indicate size constraints or visibility issues.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.

Nephro Care India Limited vs Hospital Peers

Peer Comparison - Hospital

Compare Nephro Care India Limited with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
57.1/100
69
₹220.67
65.1
Average
8.38%
Poor
11.27%
Average
0.0
Excellent
210.58%
Excellent
143.29%
Excellent
0.00%
69.1/100
993
₹109416.28
77.7
Average
12.72%
Average
14.88%
Average
0.3
Excellent
80.50%
Excellent
46.01%
Excellent
0.13%
50.2/100
8273
₹104825.94
62.7
Average
18.42%
Good
16.64%
Good
0.9
Good
33.72%
Excellent
14.15%
Good
0.26%
55.6/100
961
₹68301.24
67.8
Average
10.13%
Average
11.96%
Average
0.3
Excellent
70.31%
Excellent
10.93%
Good
0.11%
62.2/100
1920
₹39051.19
45.9
Average
24.22%
Excellent
20.75%
Excellent
0.6
Good
43.49%
Excellent
11.88%
Good
0.24%
15.4/100
741
₹34688.15
94.5
Average
8.26%
Poor
10.68%
Average
0.5
Excellent
-7.24%
Poor
-13.71%
Poor
0.75%
61/100
1208
₹33498.00
56.0
Average
16.48%
Good
19.74%
Good
0.3
Excellent
70.15%
Excellent
19.73%
Excellent
0.04%
45.1/100
784
₹27605.54
84.0
Average
18.48%
Good
15.00%
Good
1.4
Average
25.01%
Excellent
22.01%
Excellent
0.00%
51.2/100
480
₹16844.04
145.2
Average
4.76%
Poor
9.99%
Poor
0.5
Good
41.72%
Excellent
26.38%
Excellent
0.00%
54.6/100
1377
₹13410.38
52.8
Average
17.43%
Good
18.69%
Good
0.5
Good
33.66%
Excellent
16.08%
Excellent
0.23%
36.4/100
660
₹10474.40
296.2
Average
5.14%
Poor
8.56%
Poor
1.9
Average
19.34%
Excellent
15.22%
Excellent
0.00%

Nephro Care India Limited PE Ratio History

Historical price-to-earnings ratio for NEPHROCARE — last 5 years

YearEPS (₹)Price (₹)P/E Ratio
FY 20242.73₹184.0067.4x

P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.

Nephro Care India Limited Quarterly Performance

Latest quarterly metrics for NEPHROCARE — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

122.33%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

-11.42%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

143.29%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

210.58%

Compounded annual net profit growth over 5 years

Nephro Care India Limited Technical Indicators

SMA 50, SMA 200, RSI and volume signals for NEPHROCARE — calculated from daily price history

37RSI 14
Neutral — RSI 37

Momentum is balanced — neither overbought nor oversold.

SMA 50
104
▼ Price below SMA 50 — Short-term bearish
SMA 200
131
▼ Price below SMA 200 — Long-term downtrend
30-Day Avg Volume
28K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Nephro Care India Limited Financial Statements

Annual income statement, balance sheet and cash flow for Nephro Care India Limited (NEPHROCARE) — sourced from NSE/BSE filings.

Loading Financial Statements...

Fetching financial data for Nephro Care India Limited

About NEPHROCARE (Nephro Care India Limited)

Nephro Care India Limited (NEPHROCARE) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Hospital sector with a c...urrent market capitalisation of ₹220.67 (Cr). Nephro Care India Limited has delivered a Return on Equity (ROE) of 8.38% and a ROCE of 11.27%. The debt-to-equity ratio stands at 0.00, reflecting the company's capital structure. Investors tracking NEPHROCARE share price can monitor key metrics including P/E ratio, promoter holding of 61.47%, and quarterly earnings growth.

Company Details

Symbol:NEPHROCARE
Industry:Hospital
Sector:Hospital
Website:N/A

NEPHROCARE Share Price: Frequently Asked Questions

What is the current share price of Nephro Care India Limited?

Nephro Care India Limited (NEPHROCARE) trades at ₹68.85 on NSE. Market cap ₹220.67 (Cr). Educational data only.

What is the P/E ratio of Nephro Care India Limited?

Nephro Care India Limited has a P/E of 65.09x vs industry average 52.84x.

What is the Bull Run score for Nephro Care India Limited?

Nephro Care India Limited has a Bull Run score of 57.1/100 based on 25+ financial parameters.

Does Nephro Care India Limited pay dividends?

Nephro Care India Limited has a dividend yield of 0.00%. Past dividends don't guarantee future payments.

What is the ROE of Nephro Care India Limited?

Nephro Care India Limited has ROE of 8.38%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Nephro Care India Limited?

Nephro Care India Limited has debt-to-equity of 0.00.

Is Nephro Care India Limited a good investment?

Bull Run gives Nephro Care India Limited a score of 57.1/100. This is not investment advice — consult a SEBI-registered advisor.